^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Astrocytoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA...Adjuvant Treatment WHO grade 2, KPS ≥60....Preferred Regimens...RT + adjuvant TMZ...RT + concurrent and adjuvant TMZ....Other Recommended Regimens...TMZ
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Olutasidenib and Temozolomide in HGG

    Excerpt:
    ...Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)`Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)`Maximum plasma concentration [Cmax] of Olutasidenib...
    Trial ID:
    NCT06161974
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Neurooncol
    Title:

    Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma

    Published date:
    09/04/2023
    Excerpt:
    TMZ-based chemoradiation is associated with survival benefit in patients with grade 2 IDH-mutant astrocytoma.
    DOI:
    https://doi.org/10.1007/s11060-023-04418-z
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    A multicenter retrospective study of timing of chemoradiation in high-risk, grade 2, IDH-mutated astrocytoma.

    Published date:
    05/25/2023
    Excerpt:
    This study sought to evaluate the clinical characteristics and survival of patients with Grade 2 IDH mutated astrocytoma treat with adjuvant temozolomide (TMZ) based chemoradiation (tRT) compared to patients treated with observation following surgery….tRT improved PFS compared to OBS (p=0.044) with mPFS 6.17y v. 3.58y.
    DOI:
    10.1200/JCO.2023.41.16_suppl.e14035
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Neuropathol Exp Neurol
    Title:

    IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology

    Published date:
    01/12/2021
    Excerpt:
    Herein, we present 3 cases of isocitrate dehydrogenase (IDH)-mutant astrocytoma with chromosome 19q13 deletion. In the first case, the primary tumor harbored an IDH1 mutation with chromosome 1p/19q partial deletions, which covered 19q13 and exhibited a durable initial response to radiotherapy and temozolomide (TMZ) treatment. However, the tumor lost the chromosome 1p/19q partial deletions at recurrence and became resistant to TMZ.
    DOI:
    10.1093/jnen/nlaa161